DNAprint Genomics (DNAG)

[hornsky0]

July 28,03 Tony told the wall street transcripts about DNAprint Pharm. here is the opening paragraph. TWST: Could you start us off with a brief summary of DNAprint genomics?

Dr. Frudakis: DNAprint genomics is a small genomics firm that is focused on extracting value from the human genome sequence. That is clinical value, forensics value and recreational value. So we have made great progress in the forensics space and you may have heard about that through the media surrounding the Louisiana serial killer case which we helped break with genomics tests we have developed here. But our main purpose is to determine why people respond to drugs differently so that the response can be predicted beforehand. Right now we are spending most of our efforts working on solving problems associated with other people's drugs such as Lipitor or Bristol-Myer's Taxol drug. In the not so distant future, we are going to have our own drug pipeline and we will apply our talents toward solving our drugs rather than other people's drugs. But what really sets DNAprint apart from other genomics companies is that we think we are the only ones who know how to accurately determine what it is that makes people respond to drugs differently. The reason why is that we are the only company that appreciates the fact that something called population structure can be used as a tool to hone in on genomic sequences that can be used to predict response. So basically our advantage is a scientific and technical one. We do things better than even the large pharmaceutical companies do because we were comprised of young, very bright scientists who think innovation, not old school. Our founding group was comprised of a group of scientists and not a group of business people and we got the business expertise after the fact.

http://www.twst.com/notes/articles/tah617.html